Skip to main content

Month: January 2025

Digital Utilities Ventures, Inc. Announces Strategic Partnership with TradersQue LLC to Support Growth and Expansion Initiatives

MANKATO, Minn., Jan. 15, 2025 (GLOBE NEWSWIRE) — Digital Utilities Ventures (OTC: DUTV), a green solutions company focused on regenerative agriculture and clean water technologies, is pleased to announce a strategic partnership with TradersQue LLC (www.TradersQue.com). The collaboration aims to leverage TradersQue’s innovative business solutions to support DUTV’s ongoing growth and expansion efforts across the Agricultural and other new markets. This partnership will provide DUTV with essential tools and resources to enhance operational efficiency, drive sales initiatives, and optimize market strategies. By tapping into TradersQue’s SaaS solutions and affiliate network, DUTV is positioned to further its mission of delivering sustainable and innovative technologies to global markets. CEO Mark Gaalswyk commented, “We are excited...

Continue reading

Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare’s Landmark Report

VANCOUVER, British Columbia, Jan. 15, 2025 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is excited to announce that its cutting-edge anti-aging compound, TFC-1326, has been highlighted in Stonegate Healthcare Partners’ latest research report. The publication, titled “Sirona Biochem’s TFC-1326 Clinical Data Versus Retinoid Clinical Data,” provides an extensive evaluation of TFC-1326’s clinical trial performance, setting it apart from traditional retinoid treatments. The report outlines the remarkable benefits of TFC-1326, including:Boosting skin radiance Significantly reducing wrinkle depth and volume Enhancing skin elasticity and firmness Ensuring deep hydration with no irritationStonegate Healthcare’s analysis underscores TFC-1326’s ability to deliver rapid, consistent results while...

Continue reading

Ipsos successfully completes a bond issuance of €400 million

Ipsos successfully completes a bond issuance of €400 million Paris, 15 January 2025 – Ipsos, one of the world’s leading market research companies, announces the successful issuance of its first rated bond for €400 million. The bond is maturing in January 2030 and carrying a coupon of 3.75%. Ipsos is rated Baa3 with stable outlook by Moody’s and BBB with stable outlook by Fitch. The very strong investor demand, with an orderbook covering more than 9 times the size of the bond, is a testament to their confidence in Ipsos’ business model and credit profile. This substantial level of oversubscription allowed Ipsos to price the bond with a final spread significantly below initial price indication. The proceeds will be used for general corporate purposes, including the refinancing of its €300 million existing bond maturing in September 2025. DisclaimerThis...

Continue reading

Mullen Group Ltd. 2024 Year-End and Fourth Quarter Earnings Conference Call and Webcast

OKOTOKS, Alberta, Jan. 15, 2025 (GLOBE NEWSWIRE) — (TSX: MTL) Mullen Group Ltd. (“Mullen Group” and/or the “Corporation“) intends to release its 2024 Year-End and Fourth Quarter earnings results on Thursday, February 13, 2025, at 6:00 a.m. ET, and has scheduled a conference call and webcast as follows:Date: February 13, 2025   Time: 10:00 a.m. ET   Pre-Registration: registration link     Upon registering, you will receive a calendar booking by email with dial in details and a unique PIN. This process will bypass the operator and avoid the queue. Registration will remain open until the end of the conference call.   Dial-in: 1-844-763-8274 (for participants in North America)  +1-647-484-8814 (International participants)   Webcast: www.mullen-group.com   Replay: Two...

Continue reading

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (IMV) with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only treatment approved in the European Union for the treatment of SARS-CoV-2-induced ARDS. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “The European Commission’s...

Continue reading

Alstom S.A: Alstom to overhaul and modernize 181 Bi-Level commuter rail cars for Metrolinx in Ontario, Canada

                                                                                                    Mid-life overhaul and upgrades of the Bi-Level series VIII cars will begin by 2026 at Alstom’s facility in Thunder Bay and will support approximately 250 high-skilled jobs until at least 2030. The framework agreement is worth approximately 500 million CAD (approximately 340 million EUR). Alstom is a long-term and dedicated partner of Metrolinx providing rolling stock, signalling, maintenance, and rail operation services to Ontario for close to 50 years.15 January 2025 – Alstom, global leader in smart and sustainable mobility, has signed a new agreement with Metrolinx to overhaul and modernize 181 Bi-Level commuter rail cars for GO Transit, the regional public transit service for the Greater Golden Horseshoe in Ontario, Canada. The framework...

Continue reading

Sanofi: Information concerning the total number of voting rights and shares – November 2024

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)    Sanofia French société anonyme with a registered share capital of 2,537,214,304 €Registered office : 46, avenue de la Grande Armée – 75017 Paris – FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844Date   Total number of issued shares   Number of real voting rights(excluding treasury shares) Theoretical number of voting rights (including treasury shares)*October 31, 2024 1,268,922,721 1,413,173,242 1,428,504,323* Pursuant to article 223-11 of the Règlement général de l’Autorité...

Continue reading

New Toll Brothers Community, Regency at West Windsor, Open in West Windsor Township, New Jersey

WEST WINDSOR TOWNSHIP, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the grand opening of Regency at West Windsor, an exceptional active-adult community for residents 55 and over in West Windsor Township, New Jersey. This new townhome community offers low-maintenance living with luxurious amenities and modern home designs. The Toll Brothers Sales Center is now open at 2 Meade Drive in West Windsor. Located just outside of Princeton, New Jersey, this new townhome community for active adults features an array of onsite amenities in a peaceful, natural setting. Residents will be able to socialize with friends at the clubhouse, enjoy the pool and fitness center, and stroll the community walking trails with benches and birdhouses throughout. Home...

Continue reading

HP Appoints Carol Surface as Chief People Officer

PALO ALTO, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) — Today HP Inc. (NYSE: HPQ) announced the appointment of Carol Surface as Chief People Officer, starting March 24. Carol has a proven track record for building high-performance, purpose-driven teams to deliver exceptional business results. With a career spanning some of the world’s most iconic brands, Carol brings a wealth of global experience and insight to HP. Most recently, she served as Chief People Officer at Apple. Prior to that, Carol spent a decade as Chief Human Resources Officer at Medtronic, a global healthcare technology leader, where she led transformation initiatives to drive growth, including the evolution of the HR operating model. Her impressive journey includes senior leadership roles at Best Buy, where she was CHRO, and Pepsi Co, where she was instrumental in...

Continue reading

Uni-Fuels Becomes Singapore’s First Marine Fuel Provider to List in U.S.

SINGAPORE, Jan. 15, 2025 (GLOBE NEWSWIRE) — Uni-Fuels Holdings Limited (NASDAQ: UFG), (“Uni-Fuels” or the “Company”), a global provider of marine fuel solutions headquartered in Singapore, today announced its successful initial public offering (“IPO” or “Offering”) on the Nasdaq Stock Market, becoming the first Singapore-based marine fuel provider to be listed in the United States. The Offering was conducted on a firm commitment basis. R. F. Lafferty & Co., Inc. acted as the sole book-running manager for the Offering. This milestone, said Uni-Fuels, is expected to further strengthen the company’s position in the global marine fuel market and underscore its commitment to innovation, growth, and excellence within the marine fuel industry. “We are extremely honoured to be the first homegrown Singaporean marine fuel provider to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.